Variability in the Treatment of Non-ST-Segment Elevation Acute Coronary Syndrome and Its Consequences;Variabilidad en el tratamiento del síndrome coronario agudo sin elevación del segmento ST y sus consecuencias

Revista Espanola de Cardiologia Suplementos

Volumn 11, Issue SUPPL. 1, 2011, Pages 8-13

  Bonet, Ana ^a   Bardají, Alfredo ^b  

^a Hospital de Sant Joan Despi Moises Broggi   (Spain)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

Acute coronary syndrome; Prognosis; Treatment

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; ARTICLE; DIABETIC PATIENT; FEMALE; HIGH RISK PATIENT; HUMAN; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PROGNOSIS; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 79953868353     PISSN: 11313587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1131-3587(11)70003-6     Document Type: Article

References (30)

1. Fox K.A., Goodman S.G., Klein W., Brieger D., Steg P.G., Dabbous O., et al. Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002, 23:1177-1189.
2. Sonel A.F., Good C.B., Mulgund J., Roe M.T., Gibler W.B., Smith S.C., et al. Racial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes: insights from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines?). Circulation 2005, 111:1225-1232.
3. Walters D.L., Aroney C.N., Chew D.P., Bungey L., Coverdale S.G., Allan R., et al. Variations in the application of cardiac care in Australia. Results from a prospective audit of the treatment of patients presenting with chest pain. MJA 2008, 188:218-223.
4. Gulati M., Patel S., Jaffe A.S., Joseph A.J., Calvin J.E. Impact of contemporary guideline compliance on risk stratification models for acute coronary syndromes in the Registry of Acute Coronary Syndromes. Am J Cardiol 2004, 94:873-878.
5. Fox K.A.A., Anderson F.A., Dabbous O.H., Steg P.G., López-Sendón J., Van de Werf F., et al. Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events GRACE. Heart 2007, 93:177-182.
6. Yan A.T., Yan R.T., Tan M., Fung A., Cohen A., Fitchett D.H., et al. Management patterns in relation to risk stratification among patients with non-ST elevation acute coronary syndromes. Arch Intern Med 2007, 167:1009-1016.
7. Blomkalns A.L., Chen A.Y., Hochman J.S., Peterson E.D., Trynosky K., Diercks D., et al. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Large-scale observations from the CRUSADE. J Am Coll Cardiol 2005, 45:832-837.
8. Alonso J., Bueno H., Bardají A., García-Moll X., Badia X., Layola M., et al. Influencia del sexo en la mortalidad y el manejo del síndrome coronario agudo en España. Rev Esp Cardiol Supl 2008, 8:8D-22D.
9. Bassand J.-P., Hamm C.W., Ardissino D., Boersma E., Budaj A., Fernández-Avilés F., et al. Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. Rev Esp Cardiol 2007, 60:e1-e80.
10. Bueno H. Elección del tratamiento antitrombótico en pacientes con síndrome coronario agudo sin elevación del segmento ST de alto riesgo. Rev Esp Cardiol Supl 2005, 5:40C-46C.
11. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998, 339:436-443. The PURSUIT Trial Investigators.
12. Boersma E., Harrington R.A., Moliterno D.J., White H., Theroux P., Van de Werf F., et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002, 359:189-198.
13. Glaser R., Herrmann H.C., Murphy S.A., Demopoulos L.A., DiBattiste P.M., Cannon C.P., et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA 2002, 288:3124-3129.
14. Cannon C.P., Weintraub W.S., Demopoulos L.A., Vicari R., Frey M.J., Lakkis N., et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001, 344:1879-1887.
15. Bueno H., Bardají A., Fernández-Ortiz A., Marrugat J., Martí H., Heras M. Manejo del síndrome coronario agudo sin elevación del segmento ST en España. Estudio DESCARTES (Descripción del Estado de los Síndromes Coronarios Agudos en un Registro Temporal ESpañol). Rev Esp Cardiol 2005, 58:244-252.
16. Ferreira-González I., Permanyer-Miralda G., Marrugat J., Heras M., Cuñat J., Civeira E., et al. Estudio MASCARA (Manejo del Síndrome Coronario Agudo. Registro Actualizado). Resultados globales. Rev Esp Cardiol 2008, 61:803-816.
17. Franklin K., Goldberg R.J., Spencer F., Klein W., Budaj A., Brieger D., et al. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med 2004, 164:1457-1463.
18. Roffi M., Chew D.P., Mukherjee D., Bhatt D.L., White J.A., Heeschen C., et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001, 104:2767-2771.
19. Bauer T., Möllmann H., Weidinger F., Zeymer U., Seabra-Gomes R., Eberli F., et al. Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics. Clin Res Cardiol 2010, 99:375-383.
20. Arós F., Marrugat J., López-Bescos L., Cabadés A., Loma-Osorio A., Bosch X. Accessibility to Coronary Angiography and One-Year Survival After Myocardial Infarction. Am J Cardiol 2002, 90:409-412.
21. Ruiz-Nodar J.M., Cequier A., Lozano T., Fernández F., Möller I., Abán S., et al. Impacto del tipo de hospital en el tratamiento y evolución de los pacientes con síndrome coronario agudo sin elevación del ST. Rev Esp Cardiol 2010, 63:390-399.
22. Ferreira-González I., Permanyer-Miralda G., Heras M., Cuñat J., Civeira E., Arós F., et al. Patterns of use and effectiveness of early invasive strategy in non-ST-segment elevation acute coronary syndromes: An assessment by propensity score. Am Heart J 2008, 156:946-953.
23. Peterson E.D., Pollack Ch.V., Roe M.T., Parsons L.S., Littrell K.A., Canto J.G., et al. Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction observations from the national registry of myocardial infarction 4. J Am Coll Cardiol 2003, 42:45-53.
24. Théroux P., Alexander J., Dupuis J., Pesant Y., Gervais P., Grandmont D. Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. Am J Cardiol 2001, 87:375-380.
25. Dabbous O.H., Anderson F.A., Gore J.M., Eagle K.A., Fox K.A.A., Mehta R.H. Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary síndromes. Heart 2008, 94:159-165.
26. Bromberg-Marin G., Marin-Neto J.A., Parsons L.S., Canto J.C., Rogers W.J. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4). Am J Cardiol 2006, 98:1125-1131.
27. Banihashemi B., Goodman S.G., Yan R.T., Welsh R.C., Mehta S.R., Montalescot G., et al. Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: The Canadian Global Registry of Acute Coronary Events (GRACE) experience. Am Heart J 2009, 158:917-924.
28. Eagle K.A., Montoye C.K., Riba A.L., DeFranco A.C., Parrish R., Skorcz S., et al. Guideline-based standardized care is associated with substantially lower mortality in medicare patients with acute myocardial infarction. The American College of Cardiology's Guidelines Applied in Practice (GAP) Projects in Michigan. J Am Coll Cardiol 2005, 46:1242-1248.
29. Peterson E.D., Roe M.T., Mulgund J., DeLong E.R., Lytle B.L., Brindis R.G., et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA 2006, 295:1912-1920.
30. Heras M., Bueno H., Bardají A., Fernández-Ortiz A., Martí H., Marrugat J. Magnitude and consequences of undertreatment of high-risk patients with non-ST segment elevation acute coronary syndromes: insights from the DESCARTES Registry. Heart 2006, 92:1571-1576.